Insider · CIK 0001297491
Shelley B Thunen
Files at RXST (RxSight, Inc.), LENZ (LENZ Therapeutics, Inc.), AEON (AEON Biopharma, Inc.). First filing Dec 18, 2023, latest Dec 18, 2023.
In brief
Shelley B Thunen files SEC Form 4 as director and CFO at RXST (RxSight, Inc.), and also at LENZ (LENZ Therapeutics, Inc.), AEON (AEON Biopharma, Inc.). Since Dec 18, 2023, Shelley B Thunen has reported 0 open-market buys worth $0 and 1 open-market sell worth $1.6M, the latest filed on Dec 18, 2023.
A track record needs three past buys with six months of prices behind them; Shelley B Thunen has 0, so none is measured yet.
The newest scored trade: sold $1.6M of RXST on Dec 15, 2023, filed Dec 18, 2023, scored 47 (moderate), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RXST: RxSight, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 47Moderate | RxSight, Inc. | $1.6M 40,000 shares | -179% | +275% from low-1% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 1, 2024 | RXST RXSIGHT, INC. | 10,000 0.03% of outstanding | $564k | Mar 1, 2024 | $3.9M |
| Feb 6, 2024 | RXST RxSight, Inc. | 15,875 0.04% of outstanding | $738k | Feb 6, 2024 | $3.9M |
| Feb 5, 2024 | RXST RxSight, Inc. | 25,000 0.07% of outstanding | $1.2M | Feb 5, 2024 | $2.7M |
| Jan 26, 2024 | RXST RxSight, Inc. | 31,772 0.09% of outstanding | $1.5M | Jan 26, 2024 | $1.2M |
| Jan 2, 2024 | RXST RXSIGHT, INC. | 10,000 0.03% of outstanding | $392k | Jan 2, 2024 | $1.6M |
| Dec 15, 2023 | RXST RXSIGHT, INC. | 20,000 0.06% of outstanding | $787k | Dec 15, 2023 | none |
| Dec 15, 2023 | RXST RxSight, Inc. | 20,000 0.06% of outstanding | $785k | Dec 15, 2023 | none |
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | AEON AEON Biopharma, Inc. | AGrant or award Class A Common Stock | +222,684 | $0.00 | $0 | 258,705 | Jun 22, 2026 |
| Jun 15, 2026 | LENZ LENZ Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +22,100 | $0.00 | $0 | 22,100 | Jun 15, 2026 |
| Jun 11, 2025 | LENZ LENZ Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +13,500 | $0.00 | $0 | 13,500 | Jun 11, 2025 |
| May 21, 2025 | AEON AEON Biopharma, Inc. | AGrant or award Restricted Stock Unitsderivative | +308,641 | $0.00 | $0 | 308,641 | May 23, 2025 |
| Apr 14, 2025 | RXST RxSight, Inc. | MOption exercise Common Stock | +7,792 | $4.34 | $34k | 38,354 | Apr 15, 2025 |
| Apr 14, 2025 | RXST RxSight, Inc. | MOption exercise Stock Option (right to buy)derivative | -6,405 | $0.00 | $0 | 0 | Apr 15, 2025 |
| Apr 14, 2025 | RXST RxSight, Inc. | MOption exercise Stock Option (right to buy)derivative | -1,387 | $0.00 | $0 | 0 | Apr 15, 2025 |
| Mar 21, 2024 | LENZ LENZ Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +27,000 | $0.00 | $0 | 27,000 | Mar 25, 2024 |
| Mar 19, 2024 | AEON AEON Biopharma, Inc. | AGrant or award Stock Optionderivative | +16,260 | $0.00 | $0 | 16,260 | Mar 21, 2024 |
| Dec 15, 2023 | RXST RxSight, Inc. | MOption exercise Common Stock10b5-1 | +20,000 | $15.60 | $312k | 22,291 | Dec 18, 2023 |
| Dec 15, 2023 | RXST RxSight, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $39.35 | $787k | 2,291 | Dec 18, 2023 |
| Dec 15, 2023 | RXST RxSight, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -10,000 | $39.31 | $393k | 38,402 | Dec 18, 2023 |
| Dec 15, 2023 | RXST RxSight, Inc. | SOpen-market sale Common Stockindirect: See footnote10b5-1 | -10,000 | $39.32 | $393k | 28,402 | Dec 18, 2023 |
| Dec 15, 2023 | RXST RxSight, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 76,805 | Dec 18, 2023 |
Questions about Shelley B Thunen
Answered from the filings on this page, as of the latest one.
Is Shelley B Thunen buying or selling?
Not in the last 12 months. Shelley B Thunen's latest open-market trade on SEC Form 4 was sold $1.6M of RXST on Dec 15, 2023.
How did Shelley B Thunen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Shelley B Thunen has 0.
Where does Shelley B Thunen file Form 4?
Shelley B Thunen has filed Form 4 at RXST (RxSight, Inc.) as Chief Financial Officer; LENZ (LENZ Therapeutics, Inc.); AEON (AEON Biopharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.